Nancy Chang, Ph.D., is the Chairperson of the Board and has served as Director of Ansun since 2011.  She is a pioneer of the biopharmaceutical industry.  She was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors from 2007 to 2012. From 1987 to 2007, Dr. Chang served as Co-Founder, President and Chairman of Tanox, Inc., which was sold to Genentech in 2007. Prior to founding Tanox, Dr. Chang held several leadership positions at Centocor, now a division of Johnson & Johnson. She was also an Associate Professor at Baylor College of Medicine. She has served on the board of several companies, including SciClone Pharmaceuticals, Inc., Charles River Laboratories International, Inc., Inspirna . Nancy received her Doctorate in Biological Chemistry from Harvard University.

Allen Chao, Ph.D. has served as a Director at Ansun since 2010.  Dr. Chao is a pioneer in the life sciences industry.  Since January 2008, Dr. Chao has been Chairman of Newport Healthcare Advisors, LLC, a healthcare investment management and consulting company.  Dr. Chao was a co-founder of Watson Pharmaceuticals, Inc. (now Actavis plc), a specialty pharmaceutical company, serving as a director from 1985 to May 2008, Chairman of the board of directors from May 1996 to May 2008, and Chief Executive Officer from 1985 to September 2007. While at Watson, Dr. Chao oversaw the company’s growth, through internal R&D, licensing and acquisitions of pharmaceutical products and technologies, as well as mergers and acquisition activities. Dr. Chao received a Ph.D. in industrial and physical pharmacy from Purdue University in 1973. In May of 2000, he received the degree of Doctor of Science from Purdue.

Mr. Tseng joined Ruentex Group in 1992, and is currently serving as Special Assistant to the CEO of Ruentex Industries, Ltd.

Mr. Tseng was called to the English Bar in 1985. He received a B.A. from the University of Cambridge, an LL.M. from University College London, and an LL.B. from National Chengchi University.

Ms. Rachel Yu is focused on investment and research in the healthcare industry. As a veteran of the industry with extensive network and resources, she has nearly 20 years’ experience working in equity investment, secondary market and new drug research and development in both China and the US.

Prior to joining Oceanpine Capital, Rachel had worked as a Partner of CR Life Star Fund and Managing Director of Healthcare and Life Sciences of China Renaissance Capital for over seven years. She had led nearly 30 equity investments, private placements, and IPO deals with a total transaction amount of more than $3 billion over there. Rachel also worked for Gerson Lehrman Group as a Vice President, Head of Research in Beijing and Head of China’s Healthcare Practice.

Prior to that, Rachel had worked in the U.S. for more than ten years and served as an Equity Research Analyst of U.S. Healthcare industry for Deutsche Bank and other investment banks and was responsible for U.S. life science company equity research. She had also worked in the new drug development department of Genentech for 5 years, responsible for early target discovery and pre-clinical research and development.

Rachel holds an MBA from the University of Chicago, an MS degree in pharmacology from the University of Missouri, and a B.A. degree in Pharmaceutical Science from Guangdong Pharmaceutical University.

Yi Shi, Ph.D., has served as Director of Ansun since April 2018.  He is the Founder and Managing Partner of Lilly Asia Ventures, a biomedical venture capital firm with focus on China and cross-border opportunities. Prior to his current role, Yi worked at Eli Lilly and Company in business development licensing and corporate ventures. His education includes a Ph.D. in Biochemistry and an MBA degree , both from Duke University. He also has a  B.S. degree in Biology from the University of Science and Technology of China.

Michael Chao, M.D., is the Senior Managing Director of Relativity Healthcare Partners, LLC, a family office investment group dedicated to providing capital to companies developing promising technologies and/or offering novel services to address unmet needs. As a financier, Dr. Chao concentrates on investments that build preeminent healthcare companies. He has been involved with investments in various companies, including LensGen, Tanvex BioPharma, TenNor Therapeutics, EarLens, and Orphomed. He has served on the Board of Directors for MidLabs, BioAnalytix, and Owl Biomedical through successful exits.   Furthermore, Dr. Chao maintains a direct link to the healthcare community as a staff physician at the US Department of Veterans Affairs healthcare system, providing medical and surgical care for veterans and combat veterans from current and prior military conflicts.  Dr. Chao has served on Children’s Hospital of Orange County (CHOC) Foundation Board, where he chaired the Transformational Philanthropic Venture Funding Committee, which supports innovative ideas in pediatric health. Dr. Chao received his MD from University of California, Irvine and his BA in Biology from the University of Pennsylvania.

Mr. Wu has served as Director of Ansun since July of 2018.  Mr. Aimin Wu is the President and Managing Partner of Sinopharm Capital.  Prior to that, Mr. Wu served as the Chief Financial Officer of Sinopharm Group Co. Ltd. from July 2003 to December 2006. From 2007 to 2012, Mr. Wu served as the Vice President of Sinopharm Group Co. Ltd. In addition, Mr. Wu was a Director of Accord Pharma from January 2005 to April 2014, a Director of National Medicines from December 2005 to December 2008 and a supervisor of National Medicines from May 2009 to December 2011.  Mr. Wu has nearly 20 years of working experience in Chinese and international capital market operations, pharmaceutical industry strategic development, mergers and acquisitions, restructurings, business development and financial management.  Mr. Wu is a qualified accountant in the PRC.  He obtained an Executive MBA degree from Shanghai Jiao Tong University in December 2006, and a B.S.  degree in Engineering, Majoring in Economy, from Hunan University in July 1992.

Donald Payne, MBA, CPA has served as a Director at Ansun since April 2018. For the past 27 years Mr. Payne has held senior operating and financial positions in early-stage biopharmaceutical and medical device companies.  His operations experience includes authoring IND and IDE filings with the FDA, managing US and non-US clinical trials in oncology, establishing cGMP manufacturing operations, and managing preclinical efficacy and toxicology programs.  Mr. Payne has co-authored 9 scientific publications and is a co-inventor of two issued and one pending patent applications.  He has served as a director of public and private early-stage companies, including as the Chairman of the Audit Committee of a Nasdaq-listed company. As the chief financial officer of early-stage companies, he has participated in various public and private financings and listings on NYSE and Nasdaq.  He currently consults with biopharmaceutical and medical device companies focused in oncology.  Mr. Payne is a Summa Cum Laude graduate of Rice University with an MBA degree  in 1992 ( and a Summa Cum Laude graduate of Texas A&M University (1976) with a Bachelor in Business Administration.  Mr. Payne is a licensed CPA in Texas.

Karen Liu, Ph.D., is a founding partner of 3E Bioventures Capital, a healthcare focused venture investment firm which invests in new drugs and innovative devices and diagnostics.  Prior to 3E, Dr. Karen Liu was a partner of Kaiwu Capital and Managing Director at CRCI Capital, always covering healthcare investing.  Dr. Liu received her Ph.D. in Immunology from Harvard University, Master of Medical Sciences degree from Harvard University, and Bachelor of Sciences degree from Cornell University. She also received an EMBA degree from CKGSB – Chungkong Graduate School of Business in China.